STOCK TITAN
  1. Home
  2. News
  3. INSM

Insmed Inc - INSM STOCK NEWS

Welcome to our dedicated news page for Insmed (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Insmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Insmed's position in the market.

News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Insmed Incorporated (INSM) grants inducement awards to seven new employees, offering options to purchase 81,550 shares of common stock at $26.72 per share. The options have a 10-year term and a four-year vesting schedule, incentivizing employee retention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
News
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
Rhea-AI Summary
Insmed Incorporated announces the presentation of nine abstracts at the ATS 2024 International Conference, including data from the ARISE study on ARIKAYCE in patients with MAC lung disease. The company aims to share microbiologic and patient-reported respiratory symptoms data, along with insights on their respiratory portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
conferences
-
News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Insmed Incorporated (INSM) grants inducement awards to new employees, offering options to purchase 143,650 shares at $28.06 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
News
Insmed To Present at Three March Conferences
Rhea-AI Summary
Insmed Incorporated (INSM) to present at multiple investor conferences in March 2024, aiming to engage with the investment community and showcase its commitment to patients with serious and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences
-
News
Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health
Rhea-AI Summary
Insmed Incorporated partners with Jane Seymour to raise awareness of 'Unseenism' in healthcare, addressing gender and age biases. Insmed's initiative 'Speak Up in BE' aims to support bronchiectasis patients feeling unseen. Survey data reveals high percentages of women feeling overlooked in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences
-
News
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Insmed Incorporated reports strong financial results for Q4 2023 and full year, with ARIKAYCE revenue exceeding guidance. The company ends 2023 with $780 million in cash, reiterates 2024 sales guidance of $340-360 million for ARIKAYCE. Phase 3 ASPEN trial data for brensocatib expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
earnings
News
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
Rhea-AI Summary
Insmed Incorporated (Nasdaq:INSM) announced the release of its fourth-quarter and full year 2023 financial results on February 22, 2024. The company will host a conference call for investors to discuss the financial results and provide a business update. Shareholders and interested parties can participate in the conference call by dialing (888) 210-2654 or by accessing the webcast on the company's website. A replay of the call will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences earnings
-
News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Insmed Incorporated (INSM) has announced the granting of inducement awards to 24 new employees, in accordance with NASDAQ Listing Rule 5635(c)(4). The employees received options to purchase an aggregate 155,390 shares of Insmed common stock at an exercise price of $28.53 per share. The options have a 10-year term and a four-year vesting schedule, with vesting subject to the employees' continued service with Insmed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Insmed Incorporated (Nasdaq: INSM) reports unaudited global net product sales of approximately $305.2 million for ARIKAYCE in 2023, surpassing guidance, with 2024 revenues expected to be between $340 million and $360 million. Topline data from the Phase 3 ASPEN study of Brensocatib in Adult Patients with Bronchiectasis is on track for the latter part of the second quarter of 2024. Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD is completed, with topline data expected in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Insmed Incorporated (INSM) Grants Inducement Awards to New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
none
Stock INSM logo
Insmed Inc

Nasdaq:INSM

INSM Rankings

#1387 Ranked by Market Cap
#546 Ranked by Stock Gains
N/A Ranked by Dividends

INSM Stock Data

4.05B
147.09M
1.09%
103.13%
6.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bridgewater

About INSM

insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.